Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $152328.0.

  • Evoke Pharma's Gains from Investment Securities rose 2674.78% to $152328.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $152328.0, marking a year-over-year increase of 2674.78%. This contributed to the annual value of $164253.0 for FY2024, which is 683.12% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Gains from Investment Securities is $152328.0, which was up 2674.78% from $152328.0 recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Gains from Investment Securities ranged from a high of $1.3 million in Q1 2021 and a low of $6352.0 during Q2 2024
  • For the 5-year period, Evoke Pharma's Gains from Investment Securities averaged around $188277.5, with its median value being $140167.0 (2021).
  • As far as peak fluctuations go, Evoke Pharma's Gains from Investment Securities crashed by 9714.84% in 2022, and later soared by 229811.08% in 2025.
  • Evoke Pharma's Gains from Investment Securities (Quarter) stood at $140167.0 in 2021, then tumbled by 44.18% to $78247.0 in 2022, then skyrocketed by 96.49% to $153750.0 in 2023, then dropped by 21.83% to $120182.0 in 2024, then grew by 26.75% to $152328.0 in 2025.
  • Its Gains from Investment Securities stands at $152328.0 for Q3 2025, versus $152328.0 for Q2 2025 and $143915.0 for Q1 2025.